Effect of butylphthalide on new cerebral microbleeds in patients with acute ischemic stroke

Abstract

Background: To evaluate the effect of dl-3-N-butylphthalide (NBP) on new cerebral microbleeds (CMBs) in patients with acute ischemic stroke (AIS). Methods: We will prospectively enroll patients with AIS admitted to the stroke center of Jingjiang People's Hospital. Qualified participants will be randomly assigned to either the NBP group (NBP injection) or the control group (NBP injection placebo) in a ratio of 1:1. Patients will complete the brain magnetic resonance imaging within 48 hours and 14 days after stroke onset to observe the CMBs through susceptibility weighted imaging, and evaluate whether the use of NBP will affect the new CMBs in AIS patients. SPSS 20.0 will be used for statistical analyses. Result: We will provide practical and targeted results assessing the safety of NBP for AIS patients, to provide reference for clinical use of NBP. Conclusion: The stronger evidence about the effect of NBP on new CMBs in AIS patients will be provided for clinicians.

Clinical efficacy analysis of butylphthalide combined with urinary kallidinogenase in treating chronic cerebral circulatory insufficiency

“…Butylphthalide is a new class I drug launched in China in recent years, which can help patients improve brain energy metabolism and microcirculation (Jia et al., 2020 ). Butylphthalide has the following pharmacological mechanisms (Ding et al., 2020 ): ① Increase ischemic blood flow and improve microcirculation in ischemic position. ② Protect the neurons in the ischemic position and improve the function of nerve defects.…”

Efficacy and safety of butylphthalide for patients who had acute ischaemic stroke receiving intravenous thrombolysis or endovascular treatment (BAST trial): study protocol for a randomised placebo-controlled trial

“…Several reports [20][21][22][23][24] indicated that NBP may have a beneficial effect on patients with ischaemic stroke. A multicentre, randomised, double-blind and placebocontrolled study showed that the NBP treatment significantly improved the neurofunctional deficits and the two groups did not significantly differ in the rate of adverse events.…”